Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants

2020 ◽  
Vol 50 (3) ◽  
pp. 718-723 ◽  
Author(s):  
Alessandra Serrao ◽  
Benedetta Lucani ◽  
Giovanni Assanto Manfredi ◽  
Luciano Fiori ◽  
Erminia Baldacci ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Real Life ◽  
Therapy Adherence ◽  
Adherence Assessment

scholarly journals New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation

2014 ◽  
Vol 11 (7) ◽  
pp. 680-684 ◽  
Author(s):  
Josep M. Alegret ◽  
Xavier Viñolas ◽  
Miguel A. Arias ◽  
Antoni Martínez-Rubio ◽  
Pablo Rebollo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atrial Fibrillation ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants

2020 ◽  
Vol 4 (4) ◽  
pp. 586-593 ◽  
Author(s):  
Myrthe M. A. Toorop ◽  
Nienke Rein ◽  
Melchior C. Nierman ◽  
Helga W. Vermaas ◽  
Menno V. Huisman ◽  
...  
Keyword(s):  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Therapy Adherence

Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life

2017 ◽  
Vol 227 ◽  
pp. 261-266 ◽  
Author(s):  
Cecilia Becattini ◽  
Laura Franco ◽  
Jan Beyer-Westendorf ◽  
Luca Masotti ◽  
Cinzia Nitti ◽  
...  
Keyword(s):  
Vitamin K ◽  
Major Bleeding ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Real Life

Direct oral anticoagulants (DOAC) – Management of emergency situations

2017 ◽  
Vol 37 (04) ◽  
pp. 257-266 ◽  
Author(s):  
Edelgard Lindhoff-Last
Keyword(s):  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Real Life ◽  
Bleeding Complications ◽  
Severe Bleeding ◽  
Emergency Operations ◽  
Reversal Agents ◽  
Life Threatening

SummaryThe worldwide increase in the aging population and the associated increase in the prevalence of atrial fibrillation and venous thromboembolism as well as the widespread use of direct oral anticoagulants (DOAC) have resulted in an increase of the need for the management of bleeding complications and emergency operations in frail, elderly patients, in clinical practice. When severe bleeding occurs, general assessment should include evaluation of the bleeding site, onset and severity of bleeding, renal function, and concurrent medications with focus on anti-platelet drugs and nonsteroidal anti-inflammatory drugs (NSAID). The last intake of the DOAC and its residual concentration are also relevant. The site of bleeding should be immediately localized, anticoagulation should be interrupted, and local measures to stop bleeding should be taken. In life-threatening bleeding or emergency operations immediate reversal of the antithrombotic effect may be indicated. If relevant residual DOAC-concentrations are expected and surgery cannot be postponed, prothrombin complex concentrate (PCC) and/or a specific antidote should be given. While idarucizumab, the specific antidote for dabigatran, has been recently approved for clinical use, the recombinant factor X protein andexanet alfa, an antidote for the reversal of inhibitors of coagulation factor Xa, and ciraparantag, a universal antidote, are not available. Future cohort studies are necessary to assess the efficacy and safety of specific and unspecific reversal agents in “real-life” conditions. This was the rationale for introducing the RADOA-registry (RADOA: Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists), a prospective non-interventional registry, which will evaluate the effects of specific and unspecific reversal agents in patients with life-threatening bleeding or emergency operations either treated with DOACs or vitamin K antagonists.

Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis

2021 ◽  
pp. 1-10
Author(s):  
Angkawipa Trongtorsak ◽  
Sittinun Thangjui ◽  
Jakrin Kewcharoen ◽  
Natchaya Polpichai ◽  
Ratdanai Yodsuwan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Vitamin K ◽  
Meta Analysis ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Left Ventricular ◽  
Left Ventricular Thrombus ◽  
Ventricular Thrombus
Sign in / Sign up

Export Citation Format

Share Document